IGC Completes its Phase 1 Clinical Trial on Alzheimer’s Patients, Reports Safety and Tolerability September 8, 2021September 8, 2021 by Alejandro
IGC Announces Issuance of Patent for the Treatment of Alzheimer’s Disease Using THC July 22, 2021 by Alejandro
IGC Completes the Final Cohort of its Phase 1 Clinical Trial on Alzheimer’s Patients June 24, 2021June 24, 2021 by Alejandro
IGC Reports Financial Results for the Fiscal Year Ended March 31, 2021 June 15, 2021June 15, 2021 by Alejandro
IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients June 9, 2021June 9, 2021 by Alejandro
IGC Completes Cohort 1 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients May 14, 2021May 14, 2021 by Alejandro
IGC Receives Another Patent for a Cannabinoid-Based Cream for Treating Pain March 8, 2021March 9, 2021 by Alejandro
Update On IGC’s Phase 1 Clinical Trial on Alzheimer’s Patients February 22, 2021February 22, 2021 by Alejandro
IGC Reports Financial Results for December 31, 2020 Quarter February 12, 2021February 13, 2021 by Alejandro
IGC Announces Results of its 2020 Annual Shareholders Meeting January 13, 2021January 14, 2021 by Alejandro
IGC Nominates Mr. John E. Lynch to Its Board of Directors December 22, 2020December 22, 2020 by Alejandro
IGC Commences Phase 1 of Cannabinoid Clinical Trial for Alzheimer’s Patients November 23, 2020November 23, 2020 by Alejandro
